Balyasny Asset Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Balyasny Asset Management’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,154,700	Closed	-$30.7M	–	3249
2023 Q4	$30.7M	Buy	+2,154,700	New	+$24.5M	0.06%	446

Balyasny Asset Management's AMAM Position: Q1 2024 in Review

Balyasny Asset Management sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 2,154,700 shares — an estimated $30.7M sold.

Balyasny Asset Management first reported a position in AMAM in Q4 2023 and held it in 1 quarter. The position peaked at $30.7M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Balyasny Asset Management reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Balyasny Asset Management sold 2,154,700 Ambrx Biopharma Inc shares in Q1 2024, an estimated $30.7M.
Balyasny Asset Management first reported a position in Ambrx Biopharma Inc in Q4 2023 and held it in 1 quarter.
Balyasny Asset Management's Ambrx Biopharma Inc position peaked at $30.7M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.